Detection of oncogenic mutations in the EGFR gene in lung adenocarcinoma with differential sensitivity to EGFR tyrosine kinase inhibitors

Cold Spring Harbor Symposia on Quantitative Biology

Volumn 70, Issue , 2005, Pages 73-81

  Thomas, R K ^a,b   Greulich, H ^a,b   Yuza, Y ^a   Lee, J C ^a,b   Tengs, T ^a,b   Feng, W ^a,b   Chen, T H ^a,b   Nickerson, E ^c   Simons, J ^c   Egholm, M ^c   Rothberg, J M ^c   Sellers, W R ^a,b   Meyerson, M L ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b BROAD INSTITUTE OF MIT AND HARVARD   (United States)

^c 454 Life Sciences ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; ERLOTINIB; GEFITINIB; MONOCLONAL ANTIBODY; PROTEIN TYROSINE KINASE INHIBITOR;

CANCER THERAPY; CELL GROWTH; CELL STRUCTURE; CONFERENCE PAPER; DRUG RESISTANCE; DRUG SENSITIVITY; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; MUTATION; ONCOGENE; POINT MUTATION; PRIORITY JOURNAL; PROTEIN DOMAIN; RELAPSE; SENSITIVITY ANALYSIS; SOMATIC MUTATION; TUMOR BIOPSY; ARTICLE; AUTOPHOSPHORYLATION; EPIDERMAL GROWTH FACTOR RECEPTOR GENE; GENE; HIGH THROUGHPUT SEQUENCING; NON SMALL CELL LUNG CANCER; NONHUMAN;

ADENOCARCINOMA; ANIMALS; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENES, ERBB-1; HUMANS; LUNG NEOPLASMS; MICE; MUTATION; NIH 3T3 CELLS; PROTEIN KINASE INHIBITORS; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 33746420974     PISSN: 00917451     EISSN: None     Source Type: Book Series    
DOI: 10.1101/sqb.2005.70.056     Document Type: Conference Paper

References (55)

1. Amann J., Kalyankrishna S., Massion P.P., Ohm J.E., Girard L., Shigematsu H., Peyton M., Juroske D., Huang Y., Stuart Salmon J., Kim Y.H., Pollack J.R., Yanagisawa K., Gazdar A., Minna J.D., Kurie J.M., and Carbone D.P. 2005. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 65: 226.
2. Blencke S., Ullrich A., and Daub H. 2003. Mutation of threonine 766 in the epidermal growth factor receptor reveals a hotspot for resistance formation against selective tyrosine kinase inhibitors. J. Biol. Chem. 278: 15435.
3. Brambilla E., Travis W.D., Colby T.V., Corrin B., and Shimosato Y. 2001. The new World Health Organization classification of lung tumours. Eur. Respir. J. 18: 1059.
4. Brose M.S., Volpe P., Feldman M., Kumar M., Rishi I., Gerrero R., Einhorn E., Herlyn M., Minna J., Nicholson A., Roth J.A., Albelda S.M., Davies H., Cox C., Brignell G., Stephens P., Futreal P.A., Wooster R., Stratton M.R., and Weber B.L. 2002. BRAF and RAS mutations in human lung cancer and melanoma. Cancer Res. 62: 6997.
5. Cappuzzo F., Hirsch F.R., Rossi E., Bartolini S., Ceresoli G.L., Bemis L., Haney J., Witta S., Danenberg K., Domenichini I., Ludovini V., Magrini E., Gregorc V., Doglioni C., Sidoni A., Tonato M., Franklin W.A., Crino L., Bunn P.A., Jr., and Varella-Garcia M. 2005. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J. Natl. Cancer Inst. 97: 643.
6. Cools J., DeAngelo D.J., Gotlib J., Stover E.H., Legare R.D., Cortes J., Kutok J., Clark J., Galinsky I., Griffin J.D., Cross N.C., Tefferi A., Malone J., Alam R., Schrier S.L., Schmid J., Rose M., Vandenberghe P., Verhoef G., Boogaerts M., Wlodarska I., Kantarjian H., Marynen P., Coutre S.E., Stone R., and Gilliland D.G. 2003. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N. Engl. J. Med. 348: 1201.
7. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., Teague J., Woffendin H., Garnett M.J., Bottomley W., Davis N., Dicks E., Ewing R., Floyd Y., Gray K., Hall S., Hawes R., Hughes J., Kosmidou V., Menzies A., Mould C., Parker A., Stevens C., Watt S., and Hooper S., et al. 2002. Mutations of the BRAF gene in human cancer. Nature 417: 949.
8. Demetri G.D., von Mehren M., Blanke C.D., Van den Abbeele A.D., Eisenberg B., Roberts P.J., Heinrich M.C., Tuveson D.A., Singer S., Janicek M., Fletcher J.A., Silverman S.G., Silberman S.L., Capdeville R., Kiese B., Peng B., Dimitrijevic S., Druker B.J., Corless C., Fletcher C.D., and Joensuu H. 2002. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N. Engl. J. Med. 347: 472.
9. Druker B.J., Sawyers C.L., Kantarjian H., Resta D.J., Reese S.F., Ford J.M., Capdeville R., and Talpaz M. 2001a. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N. Engl. J. Med. 344: 1038.
10. Druker B.J., Tamura S., Buchdunger E., Ohno S., Segal G.M., Fanning S., Zimmermann J., and Lydon N.B. 1996. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat. Med. 2: 561.
11. Druker B.J., Talpaz M., Resta D.J., Peng B., Buchdunger E., Ford J.M., Lydon N.B., Kantarjian H., Capdeville R., Ohno-Jones S., and Sawyers C.L. 2001b. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N. Engl. J. Med. 344: 1031.
12. Engelman J.A., Janne P.A., Mermel C., Pearlberg J., Mukohara T., Fleet C., Cichowski K., Johnson B.E., and Cantley L.C. 2005. ErbB-3 mediates phosphoinositide 3-kinase activity in gefitinib-sensitive non-small cell lung cancer cell lines. Proc. Natl. Acad. Sci. 102: 3788.
13. Fiedler W., Serve H., Dohner H., Schwittay M., Ottmann O.G., O'Farrell A.M., Bello C.L., Allred R., Manning W.C., Cherrington J.M., Louie S.G., Hong W., Brega N.M., Massimini G., Scigalla P., Berdel W.E., and Hossfeld D.K. 2005. A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease. Blood 105: 986.
14. Fukuoka M., Yano S., Giaccone G., Tamura T., Nakagawa K., Douillard J.Y., Nishiwaki Y., Vansteenkiste J., Kudoh S., Rischin D., Eek R., Horai T., Noda K., Takata I., Smit E., Averbuch S., Macleod A., Feyereislova A., Dong R.P., and Baselga J. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer. J. Clin. Oncol. 21: 2237.
15. Gorre M.E., Mohammed M., Ellwood K., Hsu N., Paquette R., Rao P.N., and Sawyers C.L. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293: 876.
16. Greulich H., Chen T.-H., Feng W., Jänne P.A., Alvarez J.V., Zappaterra M., Frank D.A., Hahn W.C., Sellers W.R., and Meyerson M. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med. 2: e313.
17. Grunwald V. and Hidalgo M. 2003. Development of the epidermal growth factor receptor inhibitor OSI-774. Semin. Oncol. 30: 23.
18. Han S.W., Kim T.Y., Hwang P.G., Jeong S., Kim J., Choi I.S., Oh D.Y., Kim J.H., Kim D.W., Chung D.H., Im S.A., Kim Y.T., Lee J.S., Heo D.S., Bang Y.J., and Kim N.K. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J. Clin. Oncol. 23: 2493.
19. Heinrich M.C., Corless C.L., Duensing A., McGreevey L., Chen C.J., Joseph N., Singer S., Griffith D.J., Haley A., Town A., Demetri G.D., Fletcher C.D., and Fletcher J.A. 2003. PDGFRA activating mutations in gastrointestinal stromal tumors. Science 299: 708.
20. Hirota S., Ohashi A., Nishida T., Isozaki K., Kinoshita K., Shinomura Y., and Kitamura Y. 2003. Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors. Gastroenterology 125: 660.
21. Hirota S., Isozaki K., Moriyama Y., Hashimoto K., Nishida T., Ishiguro S., Kawano K., Hanada M., Kurata A., Takeda M., Muhammad Tunio G., Matsuzawa Y., Kanakura Y., Shinomura Y., and Kitamura Y. 1998. Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors. Science 279: 577.
22. Hirsch F.R., Varella-Garcia M., Bunn P.A., Jr., Di Maria M.V., Veve R., Bremmes R.M., Baron A.E., Zeng C., and Franklin W.A. 2003. Epidermal growth factor receptor in non-small-cell lung carcinomas: Correlation between gene copy number and protein expression and impact on prognosis. J. Clin. Oncol. 21: 3798.
23. Huang S.F., Liu H.P., Li L.H., Ku Y.C., Fu Y.N., Tsai H.Y., Chen Y.T., Lin Y.F., Chang W.C., Kuo H.P., Wu Y.C., Chen Y.R., and Tsai S.F. 2004. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan. Clin. Cancer Res. 10: 8195.
24. Jänne P.A., Engelman J.A., and Johnson B.E. 2005. Epidermal growth factor receptor mutations in non-small-cell lung cancer: Implications for treatment and tumor biology. J. Clin. Oncol. 23: 3227.
25. Jemal A., Murray T., Ward E., Samuels A., Tiwari R.C., Ghafoor A., Feuer E.J., and Thun M.J. 2005. Cancer statistics, 2005. CA Cancer J. Clin. 55: 10.
26. Kang S., Bader A.G., and Vogt P.K. 2005. Phosphatidylinositol 3-kinase mutations identified in human cancer are oncogenic. Proc. Natl. Acad. Sci. 102: 802.
27. Kobayashi S., Boggon T.J., Dayaram T., Janne P.A., Kocher O., Meyerson M., Johnson B.E., Eck M.J., Tenen D.G., and Halmos B. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 352: 786.
28. Kosaka T., Yatabe Y., Endoh H., Kuwano H., Takahashi T., and Mitsudomi T. 2004. Mutations of the epidermal growth factor receptor gene in lung cancer: Biological and clinical implications. Cancer Res. 64: 8919.
29. Kris M.G., Natale R.B., Herbst R.S., Lynch T.J., Jr., Prager D., Belani C.P., Schiller J.H., Kelly K., Spiridonidis H., Sandler A., Albain K.S., Cella D., Wolf M.K., Averbuch S.D., Ochs J.J., and Kay A.C. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: A randomized trial. J. Am. Med. Assoc. 290: 2149.
30. Kwak E.L., Sordella R., Bell D.W., Godin-Heymann N., Okimoto R.A., Brannigan B.W., Harris P.L., Driscoll D.R., Fidias P., Lynch T.J., Rabindran S.K., McGinnis J.P., Wissner A., Sharma S.V., Isselbacher K.J., Settleman J., and Haber D.A. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc. Natl. Acad. Sci. 102: 7665.
31. Lander E.S., Linton L.M., Birren B., Nusbaum C., Zody M.C., Baldwin J., Devon K., Dewar K., Doyle M., FitzHugh W., Funke R., Gage D., Harris K., Heaford A., Howland J., Kann L., Lehoczky J., LeVine R., McEwan P., McKernan K., Meldrim J., Mesirov J.P., Miranda C., Morris W., and Naylor J., et al. (International Human Genome Sequencing Consortium). 2001. Initial sequencing and analysis of the human genome. Nature 409: 860.
32. Lynch T.J., Bell D.W., Sordella R., Gurubhagavatula S., Okimoto R.A., Brannigan B.W., Harris P.L., Haserlat S.M., Supko J.G., Haluska F.G., Louis D.N., Christiani D.C., Settleman J., and Haber D.A. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350: 2129.
33. Marchetti A., Martella C., Felicioni L., Barassi F., Salvatore S., Chella A., Camplese P.P., Iarussi T., Mucilli F., Mezzetti A., Cuccurullo F., Sacco R., and Buttitta F. 2005. EGFR mutations in non-small-cell lung cancer: Analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J. Clin. Oncol. 23: 857.
34. Margulies M., Egholm, M., Altman W.E., Attiya S., Bader J.S., Bemben L.A., Berka J., Braverman M.S., Chen Y.J., Chen Z., Dewell S.B., Du L., Fierro J.M., Gomes X.V., Godwin B.C., He W., Helgesen S., Ho C.H., Irzyk G.P., Jando S.C., Alenquer M.L., Jarvie T.P., Jirage K.B., Kim J.B., and Knight J.R., et al. 2005. Genome sequencing in microfabricated high-density picolitre reactors. Nature 437: 376.
35. Miller V.A., Kris M.G., Shah N., Patel J., Azzoli C., Gomez J., Krug L.M., Pao W., Rizvi N., Pizzo B., Tyson L., Venkatraman E., Ben-Porat L., Memoli N., Zakowski M., Rusch V., and Heelan R.T. 2004. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J. Clin. Oncol. 22: 1103.
36. Mitsudomi T., Kosaka T., Endoh H., Horio Y., Hida T., Mori S., Hatooka S., Shinoda M., Takahashi T., and Yatabe Y. 2005. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J. Clin. Oncol. 23: 2513.
37. Naoki K., Chen T.H., Richards W.G., Sugarbaker D.J., and Meyerson M. 2002. Missense mutations of the BRAF gene in human lung adenocarcinoma. Cancer Res. 62: 7001.
38. Paez J.G., Janne P.A., Lee J.C., Tracy S., Greulich H., Gabriel S., Herman P., Kaye F.J., Lindeman N., Boggon T.J., Naoki K., Sasaki H., Fujii Y., Eck M.J., Sellers W.R., Johnson B.E., and Meyerson M. 2004. EGFR mutations in lung cancer: Correlation with clinical response to gefitinib therapy. Science 304: 1497.
39. Pao W., Miller V.A., Politi K.A., Riely G.J., Somwar R., Zakowski M.F., Kris M.G., and Varmus H. 2005. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2: e73.
40. Pao W., Miller V., Zakowski M., Doherty J., Politi K., Sarkaria I., Singh B., Heelan R., Rusch V., Fulton L., Mardis E., Kupfer D., Wilson R., Kris M., and Varmus H. 2004. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc. Natl. Acad. Sci. 101: 13306.
41. Perez-Soler R., Chachoua A., Hammond L.A., Rowinsky E.K., Huberman M., Karp D., Rigas J., Clark G.M., Santabarbara P., and Bonomi P. 2004. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J. Clin. Oncol. 22: 3238.
42. Risch N.J. 2000. Searching for genetic determinants in the new millennium. Nature 405: 847.
43. Rusch V., Baselga J., Cordon-Cardo C., Orazem J., Zaman M., Hoda S., McIntosh J., Kurie J., and Dmitrovsky E. 1993. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res. 53: 2379.
44. Samuels Y., Wang Z., Bardelli A., Silliman N., Ptak J., Szabo S., Yan H., Gazdar A., Powell S.M., Riggins G.J., Willson J.K., Markowitz S., Kinzler K.W., Vogelstein B., and Velculescu V.E. 2004. High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
45. Shah N.P., Nicoll J.M., Nagar B., Gorre M.E., Paquette R.L., Kuriyan J., and Sawyers C.L. 2002. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2: 117.
46. Shigematsu H., Lin L., Takahashi T., Nomura M., Suzuki M., Wistuba, II, Fong K.M., Lee H., Toyooka S., Shimizu N., Fujisawa T., Feng Z., Roth J.A., Herz J., Minna J.D., and Gazdar A.F. 2005. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J. Natl. Cancer Inst. 97: 339.
47. Sordella R., Bell D.W., Haber D.A., and Settleman J. 2004. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163.
48. Soulieres D., Senzer N.N., Vokes E.E., Hidalgo M., Agarwala S.S., and Siu L.L. 2004. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J. Clin. Oncol. 22: 77.
49. Stamos J., Sliwkowski M.X., and Eigenbrot C. 2002. Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J. Biol. Chem. 277: 46265.
50. Stone R.M., DeAngelo D.J., Klimek V., Galinsky I., Estey E., Nimer S.D., Grandin W., Lebwohl D., Wang Y., Cohen P., Fox E.A., Neuberg D., Clark J., Gilliland D.G., and Griffin J.D. 2005. Patients with acute myeloid leukemia and an activating mutation in FLT3 respond to a small-molecule FLT3 tyrosine kinase inhibitor, PKC412. Blood 105: 54.
51. Tokumo M., Toyooka S., Kiura K., Shigematsu H., Tomii K., Aoe M., Ichimura K., Tsuda T., Yano M., Tsukuda K., Tabata M., Ueoka H., Tanimoto M., Date H., Gazdar A.F., and Shimizu N. 2005. The relationship between epidermal growth factor receptor mutations and clinicopathologic features in non-small cell lung cancers. Clin. Cancer Res. 11: 1167.
52. Tracy S., Mukohara T., Hansen M., Meyerson M., Johnson B.E., and Janne P.A. 2004. Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res. 64: 7241.
53. Tuveson D.A., Weber B.L., and Herlyn M. 2003. BRAF as a potential therapeutic target in melanoma and other malignancies. Cancer Cell 4: 95.
54. Venter J.C., Adams M.D., Myers E.W., Li P.W., Mural R.J., Sutton G.G., Smith H.O., Yandell M., Evans C.A., Holt R.A., Gocayne J.D., Amanatides P., Ballew R.M., Huson D.H., Wortman J.R., Zhang Q., Kodira C.D., Zheng X.H., Chen L., Skupski M., Subramanian G., Thomas P.D., Zhang J., Gabor Miklos G.L., and Nelson C., et al. 2001. The sequence of the human genome. Science 291: 1304.
55. Wakeling A.E., Guy S.P., Woodburn J.R., Ashton S.E., Curry B.J., Barker A.J., and Gibson K.H. 2002. ZD1839 (Iressa): An orally active inhibitor of epidermal growth factor signaling with potential for cancer therapy. Cancer Res. 62: 5749.